Life Science Today copertina

Life Science Today

Life Science Today

Di: Noah Goodson PhD
Ascolta gratuitamente

A proposito di questo titolo

 Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.© 2023 Life Science Today Economia Scienza
Episodi
  • Final Episode

    Final Episode
    Dec 20 2022

    This week, I have an announcement to make.

    Find out more at
    https://LifeScienceTodayPodcast.com


    About the Show
    Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry. 
    Mostra di più Mostra meno
    5 min
  • Sanofi/Takeda, UniQure & CSL, Fog Pharma, Merck + Imago

    Sanofi/Takeda, UniQure & CSL, Fog Pharma, Merck + Imago
    Nov 30 2022

    Vaccine hesitancy, the most expensive gene therapy in the world, a $178M series D, and a $1.3B buyout

    Find out more at
    https://LifeScienceTodayPodcast.com

    Story References
    Sanofi/Takeda
    UniQure & CSL
    Fog Pharma
    Merck + Imago

    About the Show
    Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry. 
    Mostra di più Mostra meno
    9 min
  • Indivior + Opiant, Regeneron + CytomX, Rezo, Provention

    Indivior + Opiant, Regeneron + CytomX, Rezo, Provention
    Nov 22 2022

    A $145M opioid acquisition, biobucks for the holidays, a series A, and diabetes approvals

    Find out more at
    https://LifeScienceTodayPodcast.com

    Story References
    Indivior + Opiant
    Regeneron + CytomX
    Rezo
    Provention

    About the Show
    Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry. 
    Mostra di più Mostra meno
    6 min
Ancora nessuna recensione